Abstract 1646
Background
Cervical cancer ranks first among gynecologic malignancies. Neoadjuvant chemotherapy combined with surgery is currently a recommended treatment for locally advanced cervical cancer, however the patient's prognosis is still poor and easy to recur even if the chemotherapy works significantly. We need more effective assessment method for local advanced cervical cancer. Therefore, we evaluated relationship between chemotherapeutic effect and prognosis on the expression of immunological biomarkers including CD4+, CD8+ and Foxp3 pre- and post-neoadjuvant chemotherapy for locally advanced cervical cancer.
Methods
CD4+, CD8+ and Foxp3 expression by IHC in 45 cases of locally advanced (IB2-IIB) cervical cancer pre- and post-neoadjuvant chemotherapy, computer software was used to quantitatively analyzed. The relationship between IHC results and clinicopathological characteristics, chemotherapy efficacy, PFS and OS was analyzed by SPSS software.
Results
The expression of CD4, CD8 and Foxp3 in locally advanced cervical cancer before and after neoadjuvant chemotherapy was not related to patients’ age and size of tumor (P > 0.05), which was related to FIGO staging and histological grade. The expression of CD4 and CD8 increased significantly after chemotherapy (P = 0.016, P = 0.009), while the expression of FoxP3 decreased significantly (P = 0.002). There was a significant correlation between the expression of CD8 (P = 0.005), Foxp3 (P = 0.041) and PFS in locally advanced cervical cancer, while CD4 had no significant correlation (P = 0.581). However, there is no significant correlation between OS and CD4 (P = 0.686), CD8 (P = 0.858) and Foxp3 (P = 0.689).
Conclusions
CD4, CD8 and Foxp3 are associated with tumor staging and pathological grading in neoadjuvant chemotherapy for locally advanced cervical cancer, and the expression change of CD8 and Foxp3 before and after chemotherapy can be used as an independent prognostic indicator.
Clinical trial identification
Legal entity responsible for the study
Wen Di.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
2300 - AXL has a prognostic role in metastatic colorectal cancer (mCRC) and is a predictive biomarker of lack of efficacy of chemotherapy (CT) + cetuximab in RAS wild type (WT) patients (pts)
Presenter: Claudia Cardone
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2834 - Multimodal detection of homologous recombination repair gene mutations (HRRm) in a Phase II trial of olaparib plus abiraterone in metastatic castrate resistant prostate cancer (mCRPC)
Presenter: Thomas Carr
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3596 - Identification of a highly suppressive Treg subset associated to immunotherapy response
Presenter: Emilio Giunta
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3705 - A Novel Framework for Evaluating Biomarker Response Relationships in Immuno-oncology (IO)
Presenter: Jeffrey Evelhoch
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5332 - Comparison of OncoBEAM and NGS methods to detect plasma EGFR T790M mutations at progression of NSCLC
Presenter: Jessica Garcia
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5700 - Differential expression of PD-L1 and immune biomarkers by age: Decreased expression in pediatric/AYA patients with advanced cancer
Presenter: Omid Hamid
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
966 - Potential resistance mechanisms revealed primary resistance to crizotinib in ROS1+ non-small-cell lung cancer using next generation sequencing: A multicenter study
Presenter: Quxia Zhang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2171 - Prevalence of CLDN18.2, HER2, and PD-L1 in Gastric Cancer Samples
Presenter: Diarmuid Moran
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2318 - Epigenetic markers in circulating cell-free DNA for detection of early stage colorectal cancer
Presenter: Yanqun Liu
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3625 - Detection and clearance of RET variants in plasma cell free DNA (cfDNA) from patients (pts) treated with LOXO-292
Presenter: Benjamin Besse
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract